August 3, 2014 | Israeli pharmaceutical company BioBlast announced that it raised $37 million in its NASDAQ IPO last week. The company priced 3,200,000 ordinary shares at $11 per share making gross proceeds of $35.2 million. The company also granted the underwriters 30 days to purchase up to 480,000 additional shares. BioBlasts offering, trading under the ticker ORPN is expected to close on August 5, 2014, subject to customary closings. BioBlast is an Israeli clinical stage biotechnology company founded in 2012 developing treatments for rare and ultra-rare genetic diseases.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli Startups Create Powerful Drone-Detecting Software
September 28, 2023

Model Sees Daylight As Boost For Hospitalized Patients’ Health
September 28, 2023

Solar Panels On A Roll Certified As Safe For Use In US, Europe
September 28, 2023

US Soldiers, Vets To Get Israeli-Made Helmets To Treat Depression
September 27, 2023
Facebook comments